By

Dylan Neel

4
Apr
2024

How CymaBay Survived a Safety Scare

In November 2019, Sujal Shah was the CEO of a public company with two promising late-stage clinical trials underway. The company was worth more than $900 million.  A couple months later, he found himself cornered in a parking lot by an activist investor—one of a handful pressuring him to shut down and liquidate his company CymaBay Therapeutics. “I can smile...
Read More